Citation Impact
Citing Papers
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
2012 Science
Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
2012
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
2011
Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation
2007
Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling
2011
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
2010
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer
2013
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
2008
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
2012
Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
2013
Cancer statistics, 2023
2023 Standout
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Proteomic Analysis of Exosomes from Mutant KRAS Colon Cancer Cells Identifies Intercellular Transfer of Mutant KRAS
2012
Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution
2024 StandoutNobel
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
mTOR Signaling in Growth Control and Disease
2012 Standout
A view on drug resistance in cancer
2019 StandoutNature
Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib
2007
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
2013 StandoutNature
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Integrating liquid biopsies into the management of cancer
2017
Lung Cancer
2008 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer
2006
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Head and neck cancer
2008 Standout
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
The biology and function of fibroblasts in cancer
2016 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
2010
The Cancer Genome Atlas Pan-Cancer analysis project
2013 Standout
Cancer stem cells revisited
2017 Standout
Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer
2016
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Correlation between morphology and EGFR mutations in lung adenocarcinomas
2008
Lung cancer: current therapies and new targeted treatments
2016 Standout
Colorectal cancer
2019 Standout
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer
2012
ErbBs in lung cancer
2008
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors
2007
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
2008
A Translational View of the Molecular Pathogenesis of Lung Cancer
2007
mTOR: from growth signal integration to cancer, diabetes and ageing
2010 Standout
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer
2011
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
2007
EMT: 2016
2016 Standout
Cancer stem cells, a fuzzy evolving concept: A cell population or a cell property?
2013
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
Rates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay
2010
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
2014 Standout
A guide to deep learning in healthcare
2018 Standout
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
2008
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
2012
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Quantitative and sensitive detection of rare mutations using droplet-based microfluidics
2011
The PI3K Pathway in Human Disease
2017 Standout
Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
2015
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
2020 Nature
Metastatic colonization by circulating tumour cells
2016 StandoutNature
De novo discovery of mutated driver pathways in cancer
2011
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
2014 Standout
A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA
2011
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Cancer Stem Cells: Basic Concepts and Therapeutic Implications
2016
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms
2015
Further refining 2020 ESGO /ESTRO /ESP molecular risk classes in patients with early‐stage endometrial cancer: A propensity score–matched analysis
2022
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
2012
Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
2012
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
2008
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
2011
The global burden of lung cancer: current status and future trends
2023
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
2017
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
2008
Cancer Genome Landscapes
2013 StandoutScience
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
2009
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
2010
Emerging Droplet Microfluidics
2017 Standout
A Non-Cross-Linking Platinum−Acridine Agent with Potent Activity in Non-Small-Cell Lung Cancer
2008
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
2009
Works of Junichi Soh being referenced
Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells
2013
Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
2011
Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
2008
Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
2009
PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
2008
Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer
2007
Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations
2014
The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor
2011
Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
2009
Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR
2003
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer
2007
Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer
2006
The impact of epidermal growth factor receptor gene status on gefitinib‐treated Japanese patients with non‐small‐cell lung cancer
2006
Estimation of age-related DNA degradation from formalin-fixed and paraffin-embedded tissue according to the extraction methods
2017
EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib
2007
Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer
2006
The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer
2007